NATCO announces Launch of First Generic Version of Nexavar® (Sorafenib) Tablets in the U.S. Market

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the launch of the first generic version of Nexavar® (Sorafenib) Tablets in 200 mg strength today in the U.S. market. The product will be launched by NATCO's commercial partner Viatris, a global pharmaceutical company.

Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC). For more information refer to the full prescribing information or other medical resources.

Nexavar® registered sales of USD 69.7 million for the year ending December 2021 as per industry sales data.

Nexavar® is a registered trademark of Bayer Healthcare Pharmaceuticals Inc. All brand names and trademarks are the property of their respective owners.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 692.05 as compared to the previous close of Rs. 665.70. The total number of shares traded during the day was 72360 in over 6739 trades.

The stock hit an intraday high of Rs. 697.95 and intraday low of 607.95. The net turnover during the day was Rs. 47214103.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Nexavar GenericVersion SorafenibTabelts USMarket